The world's largest recombinant human albumin fermenter system undertaken by Morimatsu has been successfully shipped, which will help the customer to build recombinant human albumin drug substance and drug product manufacturing bases. Morimatsu is responsible for the design, manufacture, installation, testing, commissioning, operation, maintenance, and after-sales services of all equipment in this project.
Besides already delivered the set of 100,000L fermentation tank system, Morimatsu shipped another 4 sets of 100,000L scale of fermentation and supporting purification and preparation production lines. Among which, the upstream fermentation part includes a series of seed tanks, fermenters, medium preparation tanks, feeding tanks, and CIP stations for serving these systems.
The project meets FDA and GMP specifications, with stable process and world-leading quality standards. After completion, the drug substance and drug product will be supplied to the global market, and the production capacity of 100 tons of recombinant human albumin will be achieved after full completion.
So far, there has been no clinical application of recombinant human albumin injection globally. Therefore the completion of this project will contribute to fill the gap of first-in-class innovative drugs in the world.
The smooth delivery of this project not only demonstrates Morimatsu's excellent manufacturing strength and overall delivery capability in the field of large-scale fermenter equipment, but also helps customers’ construction of innovative drug production bases, as well as continuously promotes global biopharmaceutical innovation and human health steady improvement.
About Morimatsu Life Science
Morimatsu Life Science is the sanitary business segment of Morimatsu International Holding Co., Ltd. (Morimatsu International, stock code: 2155.HK), covering industries such as pharmaceuticals, biopharmaceuticals, FMCG, cosmetic and electronic chemicals, and mainly includes Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd., Morimatsu (Suzhou) Life Technology Co., Ltd., Shanghai Morimatsu Biotechnology Co., Ltd., Pharmadule Morimatsu AB (Sweden) and other companies and their affiliates, focusing on the research and development, manufacturing and sales of products in related fields.
Morimatsu, founded in Japan and taken root in China, has developed into a multi-national company that embraces globalization, masters core technology, and gains rich experience from project implementation in diverse fields including core equipment, process systems, and engineering solutions. Starting from its advanced manufacturing base in China, Morimatsu International has opened subsidiaries in Sweden, the United States, India and Italy, and has delivered different forms of products and services to more than 40 countries and regions so far, by virtue of its global footprint of efficient and professional team.
The information in this press release may include some forward-looking statements. Such statements are essentially susceptible to considerable risks and uncertainties. The use of “predicted”, “believed”, “forecast”, “planned” and/or other similar words/phrases in all statements related to our company is to indicate that the statements are forward-looking ones. Our company undertakes no obligation to constantly revise such predicted statements.
Forward-looking statements are based on our company management’s current perspectives, assumptions, expectations, estimations, predictions and understanding of future affairs at the time of the making of such statements. Such statements are not guaranties of future development and are susceptible to the impact of risks, uncertainties and other factors; some are beyond the control of our company and unpredictable. Subject to the influence of future changes and development in our business, competition environment, political, economic, legal and social conditions, the actual outcomes may differ significantly from the information contained in the forward-looking statements.